Trgovina Rigel - RIGL CFD
Dodaj med priljubljene- Povzetek
- Zgodovinski podatki
- Dogodki
- Izkaz poslovnega izida
- Bilanca stanja
- Denarni tok
- Lastništvo
Razmik | 0.05 | ||||||||
Nočna pristojbina za nakup
Long position overnight fee
Pojdi na platformo | -0.025457% | ||||||||
Nočna pristojbina za prodajo
Short position overnight fee
Pojdi na platformo | 0.003235% | ||||||||
Čas nočne pristojbine | 21:00 (UTC) | ||||||||
Min. tržena količina | 1 | ||||||||
Valuta | USD | ||||||||
Kritje | 20% | ||||||||
Borza | United States of America | ||||||||
Provizija na trgovanje | 0% |
*Information provided by Capital.com
Rigel Pharmaceuticals Inc ESG Risk Ratings
‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.
Predhodno. Zapri* | 1.26 |
Odpri* | 1.23 |
Enoletna sprememba* | -34.22% |
Dnevni razpon* | 1.23 - 1.33 |
Razpon 52 wk | 0.64-2.04 |
Povprečni obseg (10 dni) | 5.26M |
Povprečni obseg (3 meseci) | 66.76M |
Tržna kapitalizacija | 229.24M |
Razmerje P/E | -100.00K |
Število delnic v obtoku | 173.67M |
Prihodki | 129.58M |
EPS | -0.26 |
Dividenda (donosnost v %) | N/A |
Beta | 0.73 |
Datum naslednjega zaslužka | Jul 31, 2023 |
Vse podatke je zagotovil Refinitiv, razen podatkov, označenih z zvezdico, ki so *podatki, ki jih je zagotovil Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Zapiranje | Change | Change (%) | Odpiranje | High | Low |
---|---|---|---|---|---|---|
May 26, 2023 | 1.29 | 0.01 | 0.78% | 1.28 | 1.33 | 1.23 |
May 25, 2023 | 1.26 | -0.06 | -4.55% | 1.32 | 1.33 | 1.23 |
May 24, 2023 | 1.31 | -0.09 | -6.43% | 1.40 | 1.40 | 1.29 |
May 23, 2023 | 1.39 | -0.09 | -6.08% | 1.48 | 1.49 | 1.34 |
May 22, 2023 | 1.49 | 0.00 | 0.00% | 1.49 | 1.58 | 1.39 |
May 19, 2023 | 1.55 | 0.18 | 13.14% | 1.37 | 1.61 | 1.31 |
May 18, 2023 | 1.27 | -0.45 | -26.16% | 1.72 | 1.93 | 1.20 |
May 17, 2023 | 1.80 | 0.53 | 41.73% | 1.27 | 1.85 | 1.24 |
May 16, 2023 | 1.27 | -0.05 | -3.79% | 1.32 | 1.32 | 1.25 |
May 15, 2023 | 1.31 | 0.09 | 7.38% | 1.22 | 1.39 | 1.21 |
May 12, 2023 | 1.22 | 0.09 | 7.96% | 1.13 | 1.28 | 1.12 |
May 11, 2023 | 1.13 | 0.00 | 0.00% | 1.13 | 1.16 | 1.11 |
May 10, 2023 | 1.16 | 0.03 | 2.65% | 1.13 | 1.16 | 1.10 |
May 9, 2023 | 1.13 | -0.02 | -1.74% | 1.15 | 1.15 | 1.10 |
May 8, 2023 | 1.17 | 0.03 | 2.63% | 1.14 | 1.17 | 1.12 |
May 5, 2023 | 1.15 | 0.01 | 0.88% | 1.14 | 1.16 | 1.12 |
May 4, 2023 | 1.14 | 0.03 | 2.70% | 1.11 | 1.15 | 1.08 |
May 3, 2023 | 1.13 | -0.01 | -0.88% | 1.14 | 1.16 | 1.09 |
May 2, 2023 | 1.11 | -0.04 | -3.48% | 1.15 | 1.18 | 1.11 |
May 1, 2023 | 1.17 | 0.08 | 7.34% | 1.09 | 1.18 | 1.08 |
Rigel Events
Čas (UTC) (UTC) | Država | Dogodek |
---|---|---|
Monday, July 31, 2023 | ||
Čas (UTC) (UTC) 10:59 | Država US
| Dogodek Q2 2023 Rigel Pharmaceuticals Inc Earnings Release Q2 2023 Rigel Pharmaceuticals Inc Earnings ReleaseForecast -Previous - |
Wednesday, November 1, 2023 | ||
Čas (UTC) (UTC) 10:59 | Država US
| Dogodek Q3 2023 Rigel Pharmaceuticals Inc Earnings Release Q3 2023 Rigel Pharmaceuticals Inc Earnings ReleaseForecast -Previous - |
- Letni
- Četrtletno
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Skupni prihodki | 120.242 | 149.236 | 108.621 | 59.288 | 44.509 |
Prihodki | 120.242 | 149.236 | 108.621 | 59.288 | 44.509 |
Celotni odhodki iz poslovanja | 175.792 | 161.732 | 137.594 | 128.379 | 117.192 |
Celotna prodaja/splošni/upravni stroški Odhodki | 112.451 | 91.891 | 76.598 | 74.588 | 70.002 |
Raziskave in razvoj | 60.272 | 65.237 | 60.101 | 52.885 | 46.903 |
Nenavadni odhodki (prihodki) | 1.32 | 3.521 | 0 | ||
Prihodki iz poslovanja | -55.55 | -12.496 | -28.973 | -69.091 | -72.683 |
Prihodki (odhodki) od obresti, neto Neoperativni | -3.023 | -4.813 | -0.771 | 2.197 | 2.203 |
Gain (Loss) on Sale of Assets | 0 | 0 | |||
Čisti dobiček pred obdavčitvijo | -58.573 | -17.309 | -29.744 | -66.894 | -70.48 |
Čisti dobiček po davkih | -58.573 | -17.914 | -29.744 | -66.894 | -70.48 |
Čisti dobiček pred dodatnimi postavkami | -58.573 | -17.914 | -29.744 | -66.894 | -70.48 |
Čisti dobiček | -58.573 | -17.914 | -29.744 | -66.894 | -70.48 |
Prihodek, ki je na razpolago navadnim delničarjem, brez dodatnih postavk | -58.573 | -17.914 | -29.744 | -66.894 | -70.48 |
Prihodek, ki je na razpolago skupnemu dobičku, vključno z dodatnimi postavkami | -58.573 | -17.914 | -29.744 | -66.894 | -70.48 |
Popravljen čisti dobiček | -58.573 | -17.914 | -29.744 | -66.894 | -70.48 |
Popravljene ponderirane povprečne delnice | 172.406 | 170.492 | 168.754 | 167.4 | 160.529 |
Popravljen dobiček na delnico brez upoštevanja izrednih postavk | -0.33974 | -0.10507 | -0.17626 | -0.39961 | -0.43905 |
Popravljen normalizirani dobiček na enoto čistega dobička | -0.33208 | -0.09165 | -0.17626 | -0.39961 | -0.43905 |
Skupaj izredne postavke | |||||
Celotni stroški prihodkov | 1.749 | 1.083 | 0.895 | 0.906 | 0.287 |
Bruto dobiček | 118.493 | 148.153 | 107.726 | 58.382 | 44.222 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Skupni prihodki | 26.07 | 51.278 | 22.41 | 29.819 | 16.735 |
Prihodki | 26.07 | 51.278 | 22.41 | 29.819 | 16.735 |
Celotni stroški prihodkov | 0.977 | 0.342 | 0.25 | 1.036 | 0.121 |
Bruto dobiček | 25.093 | 50.936 | 22.16 | 28.783 | 16.614 |
Celotni odhodki iz poslovanja | 38.795 | 49.199 | 40.813 | 42.784 | 42.996 |
Celotna prodaja/splošni/upravni stroški Odhodki | 27.729 | 32.172 | 25.897 | 26.981 | 27.401 |
Raziskave in razvoj | 10.089 | 15.365 | 14.666 | 14.767 | 15.474 |
Prihodki iz poslovanja | -12.725 | 2.079 | -18.403 | -12.965 | -26.261 |
Prihodki (odhodki) od obresti, neto Neoperativni | -0.811 | -0.678 | -0.634 | -0.527 | -1.184 |
Čisti dobiček pred obdavčitvijo | -13.536 | 1.401 | -19.037 | -13.492 | -27.445 |
Čisti dobiček po davkih | -13.536 | 1.401 | -19.037 | -13.492 | -27.445 |
Čisti dobiček pred dodatnimi postavkami | -13.536 | 1.401 | -19.037 | -13.492 | -27.445 |
Čisti dobiček | -13.536 | 1.401 | -19.037 | -13.492 | -27.445 |
Prihodek, ki je na razpolago navadnim delničarjem, brez dodatnih postavk | -13.536 | 1.401 | -19.037 | -13.492 | -27.445 |
Prihodek, ki je na razpolago skupnemu dobičku, vključno z dodatnimi postavkami | -13.536 | 1.401 | -19.037 | -13.492 | -27.445 |
Popravljen čisti dobiček | -13.536 | 1.401 | -19.037 | -13.492 | -27.445 |
Popravljene ponderirane povprečne delnice | 173.568 | 140.1 | 172.836 | 172.147 | 171.774 |
Popravljen dobiček na delnico brez upoštevanja izrednih postavk | -0.07799 | 0.01 | -0.11014 | -0.07837 | -0.15977 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Popravljen normalizirani dobiček na enoto čistega dobička | -0.07799 | 0.01942 | -0.11014 | -0.07837 | -0.15977 |
Nenavadni odhodki (prihodki) | 1.32 |
- Letni
- Četrtletno
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Kratkoročna sredstva skupaj | 115.903 | 154.467 | 88.983 | 119.005 | 136.987 |
Denarna sredstva in kratkoročne naložbe | 58.206 | 124.967 | 57.327 | 98.078 | 128.537 |
Denarna sredstva in ustrezniki | 24.459 | 18.89 | 30.373 | 22.521 | 76.322 |
Kratkoročne naložbe | 33.747 | 106.077 | 26.954 | 75.557 | 52.215 |
Celotne terjatve, neto | 40.32 | 15.472 | 15.973 | 10.111 | 4.077 |
Accounts Receivable - Trade, Net | 40.32 | 15.472 | 15.973 | 10.111 | 4.077 |
Prepaid Expenses | 8.259 | 7.412 | 14.045 | 9.462 | 3.479 |
Total Assets | 134.279 | 167.328 | 110.378 | 147.569 | 139.109 |
Property/Plant/Equipment, Total - Net | 2.787 | 11.887 | 20.571 | 27.868 | 1.387 |
Property/Plant/Equipment, Total - Gross | 13.594 | 26.438 | 34.247 | 40.913 | 14.241 |
Accumulated Depreciation, Total | -10.807 | -14.551 | -13.676 | -13.045 | -12.854 |
Other Long Term Assets, Total | 0.64 | 0.974 | 0.824 | 0.696 | 0.735 |
Total Current Liabilities | 65.211 | 63.554 | 40.841 | 58.212 | 27.734 |
Accounts Payable | 22.508 | 3.795 | 3.707 | 4.152 | 6.391 |
Accrued Expenses | 24.192 | 43.657 | 34.116 | 28.772 | 20.313 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 18.511 | 16.102 | 3.018 | 25.288 | 1.03 |
Total Liabilities | 147.895 | 136.954 | 76.352 | 93.754 | 29.232 |
Total Long Term Debt | 39.448 | 19.914 | 19.815 | 9.81 | 0 |
Other Liabilities, Total | 43.236 | 53.486 | 15.696 | 25.732 | 1.498 |
Total Equity | -13.616 | 30.374 | 34.026 | 53.815 | 109.877 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
Common Stock | 0.174 | 0.172 | 0.169 | 0.168 | 0.167 |
Additional Paid-In Capital | 1368.82 | 1354.19 | 1339.83 | 1329.85 | 1319.07 |
Retained Earnings (Accumulated Deficit) | -1382.46 | -1323.89 | -1305.97 | -1276.23 | -1209.33 |
Other Equity, Total | -0.153 | -0.102 | -0.004 | 0.023 | -0.024 |
Total Liabilities & Shareholders’ Equity | 134.279 | 167.328 | 110.378 | 147.569 | 139.109 |
Total Common Shares Outstanding | 173.399 | 171.602 | 169.317 | 167.988 | 167.172 |
Total Inventory | 9.118 | 6.616 | 1.638 | 1.354 | 0.894 |
Long Term Debt | 39.448 | 19.914 | 19.815 | 9.81 | |
Intangibles, Net | 14.949 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Kratkoročna sredstva skupaj | 106.972 | 115.903 | 110.44 | 120.521 | 138.938 |
Denarna sredstva in kratkoročne naložbe | 58.662 | 58.206 | 81.642 | 89.166 | 107.519 |
Denarna sredstva in ustrezniki | 40.285 | 24.459 | 29.866 | 27.201 | 24.679 |
Kratkoročne naložbe | 18.377 | 33.747 | 51.776 | 61.965 | 82.84 |
Celotne terjatve, neto | 29.366 | 40.32 | 15.525 | 17.198 | 15.24 |
Accounts Receivable - Trade, Net | 29.366 | 40.32 | 15.525 | 17.198 | 15.24 |
Total Inventory | 11.077 | 9.118 | 7.116 | 6.218 | 6.764 |
Prepaid Expenses | 7.867 | 8.259 | 6.157 | 7.939 | 9.415 |
Total Assets | 123.612 | 134.279 | 115.609 | 128.001 | 149.074 |
Property/Plant/Equipment, Total - Net | 1.417 | 2.787 | 4.685 | 7.077 | 9.672 |
Other Long Term Assets, Total | 0.542 | 0.64 | 0.484 | 0.403 | 0.464 |
Total Current Liabilities | 45.518 | 65.211 | 47.265 | 54.955 | 59.225 |
Accounts Payable | 6.295 | 22.508 | 2.721 | 2.155 | 4.614 |
Accrued Expenses | 18.146 | 24.192 | 37.263 | 39.434 | 40.921 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 21.077 | 18.511 | 7.281 | 13.366 | 13.69 |
Total Liabilities | 147.869 | 147.895 | 135.443 | 131.678 | 142.276 |
Total Long Term Debt | 59.484 | 39.448 | 39.468 | 29.835 | 29.847 |
Long Term Debt | 59.484 | 39.448 | 39.468 | 29.835 | 29.847 |
Other Liabilities, Total | 42.867 | 43.236 | 48.71 | 46.888 | 53.204 |
Total Equity | -24.257 | -13.616 | -19.834 | -3.677 | 6.798 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
Common Stock | 0.174 | 0.174 | 0.173 | 0.173 | 0.172 |
Additional Paid-In Capital | 1371.59 | 1368.82 | 1364.14 | 1361.41 | 1358.37 |
Retained Earnings (Accumulated Deficit) | -1395.99 | -1382.46 | -1383.86 | -1364.82 | -1351.33 |
Other Equity, Total | -0.027 | -0.153 | -0.286 | -0.438 | -0.416 |
Total Liabilities & Shareholders’ Equity | 123.612 | 134.279 | 115.609 | 128.001 | 149.074 |
Total Common Shares Outstanding | 173.666 | 173.399 | 172.836 | 172.836 | 172.045 |
Intangibles, Net | 14.681 | 14.949 |
- Letni
- Četrtletno
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Čisti prihodki/začetna postavka | -58.573 | -17.914 | -29.744 | -66.894 | -70.48 |
Denarna sredstva iz poslovanja | -73.758 | 5.878 | -52.185 | -41.51 | -58.826 |
Denarna sredstva iz poslovanja | 0.998 | 1.162 | 0.706 | 0.683 | 0.594 |
Nedenarne postavke | 12.866 | 12.912 | 7.175 | 8.042 | 6.938 |
Spremembe v obratnem kapitalu | -29.049 | 9.718 | -30.322 | 16.659 | 4.122 |
Denarna sredstva pri naložbenju | 72.777 | -80.036 | 47.466 | -23.656 | 24.964 |
Kapitalski izdatki | -0.45 | -0.627 | -1.262 | -1.455 | -1.106 |
Celotne druge postavke denarnih tokov pri naložbenju | 73.227 | -79.409 | 48.728 | -22.201 | 26.07 |
Denarna sredstva pri financiranju | 6.55 | 62.675 | 12.571 | 11.365 | 71.894 |
Izdaja (odplačilo) delnic, neto | 2.124 | 4.775 | 2.596 | 1.576 | 71.894 |
Neto sprememba denarnih sredstev | 5.569 | -11.483 | 7.852 | -53.801 | 38.032 |
Denarna sredstva Plačane obresti | 2.495 | 1.5 | 1.18 | 0.137 | |
Izdaja (odplačilo) dolga, neto | 19.542 | 0 | 9.975 | 9.789 | |
Postavke denarnega toka pri financiranju | -15.116 | 57.9 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -13.536 | -58.573 | -59.974 | -40.937 | -27.445 |
Cash From Operating Activities | -4.074 | -73.758 | -51.849 | -38.548 | -25.637 |
Cash From Operating Activities | 0.357 | 0.998 | 0.714 | 0.474 | 0.237 |
Non-Cash Items | 3.037 | 12.866 | 8.638 | 6.134 | 3.917 |
Cash Interest Paid | 1.011 | 2.495 | 1.549 | 0.951 | 0.393 |
Changes in Working Capital | 6.068 | -29.049 | -1.227 | -4.219 | -2.346 |
Cash From Investing Activities | 0.777 | 72.777 | 54.179 | 43.724 | 22.629 |
Capital Expenditures | -15 | -0.45 | -0.377 | -0.188 | -0.224 |
Other Investing Cash Flow Items, Total | 15.777 | 73.227 | 54.556 | 43.912 | 22.853 |
Cash From Financing Activities | 19.123 | 6.55 | 8.646 | 3.135 | 8.797 |
Issuance (Retirement) of Stock, Net | 0.001 | 2.124 | 1.539 | 1.539 | 0.94 |
Net Change in Cash | 15.826 | 5.569 | 10.976 | 8.311 | 5.789 |
Financing Cash Flow Items | -0.828 | -15.116 | -12.435 | -8.346 | -2.118 |
Issuance (Retirement) of Debt, Net | 19.95 | 19.542 | 19.542 | 9.942 | 9.975 |
Ime vlagatelja | Vrsta vlagatelja | Odstotek neporavnanih obveznosti | Delnice v lasti | Sprememba delnic | Datum imetništva | Ocena prometa |
---|---|---|---|---|---|---|
Armistice Capital LLC | Hedge Fund | 9.8027 | 17024000 | 68000 | 2023-03-31 | HIGH |
Soleus Capital Management, L.P. | Hedge Fund | 7.3722 | 12803015 | 3580000 | 2023-03-31 | HIGH |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 6.7076 | 11648803 | -309585 | 2023-03-31 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 6.5408 | 11359133 | -724663 | 2023-03-31 | LOW |
Millennium Management LLC | Hedge Fund | 3.0156 | 5237117 | 2048839 | 2023-03-31 | HIGH |
Two Sigma Investments, LP | Hedge Fund | 2.6663 | 4630551 | 1268842 | 2023-03-31 | HIGH |
Jacobs Levy Equity Management, Inc. | Investment Advisor/Hedge Fund | 2.2511 | 3909492 | -509370 | 2023-03-31 | MED |
Acadian Asset Management LLC | Investment Advisor/Hedge Fund | 2.1441 | 3723563 | 182062 | 2023-03-31 | MED |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 1.9843 | 3446155 | 71241 | 2023-03-31 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.8856 | 3274591 | 125121 | 2023-03-31 | LOW |
Fidelity Management & Research Company LLC | Investment Advisor | 1.6332 | 2836324 | -6055683 | 2023-03-31 | LOW |
Nuveen LLC | Pension Fund | 1.5836 | 2750119 | 33858 | 2023-03-31 | LOW |
Tamarack Advisers, LP | Hedge Fund | 1.1516 | 2000000 | -300000 | 2023-03-31 | |
Renaissance Technologies LLC | Hedge Fund | 1.1394 | 1978718 | 1180218 | 2023-03-31 | HIGH |
Sphera Funds Management Ltd. | Hedge Fund | 1.0819 | 1878845 | -400000 | 2023-03-31 | MED |
Quoniam Asset Management GmbH | Investment Advisor/Hedge Fund | 1.0494 | 1822376 | -382044 | 2023-03-31 | MED |
BlackRock Financial Management, Inc. | Investment Advisor/Hedge Fund | 1.0106 | 1755094 | 76617 | 2023-03-31 | LOW |
Rodriguez (Raul R) | Individual Investor | 0.9678 | 1680713 | -20340 | 2023-02-06 | |
Macquarie Investment Management | Investment Advisor | 0.9213 | 1600000 | 0 | 2023-03-31 | LOW |
CM Management, LLC | Investment Advisor | 0.8637 | 1500000 | 0 | 2023-03-31 | MED |
Zakaj izbrati Capital.com? Številke govorijo same zase.
Capital.com Group530K+
Borzni posredniki
87K+
Aktivne stranke mesečno
$46M+
Mesečni obseg naložb
$31M+
Dvigi vsak mesec
Kalkulator trgovanja
Izračunajte svoj hipotetični P&L, če bi trgovino s CFD odprli na določen datum (izberite datum) in jo zaprli na drug datum (izberite datum).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Rigel Company profile
O družbi Rigel
Rigel Pharmaceuticals, Inc. je biotehnološko podjetje. Podjetje se ukvarja z odkrivanjem, razvojem in zagotavljanjem zdravil z majhnimi molekulami, ki izboljšujejo življenje bolnikov s hematološkimi motnjami, rakom in redkimi imunskimi boleznimi. Raziskave družbe se osredotočajo na signalne poti, ki so ključne za mehanizme bolezni. Izdelek družbe, tablete TAVALISSE (fostamatiniba dinatrijevega heksahidrata), zaviralec tirozinske kinaze vranice (SYK), za zdravljenje odraslih bolnikov s kronično imunsko trombocitopenijo (ITP). Izdelek družbe je komercialno dostopen tudi v Evropi, Združenem kraljestvu (UK) (TAVLESSE) in Kanadi (TAVALISSE) za zdravljenje kronične ITP pri odraslih bolnikih. Njeni klinični programi vključujejo program zaviralca kinaze, povezane z interlevkinskimi receptorji (IRAK), in program zaviralca serin/treonin-proteinske kinaze (RIPK1), ki je v kliničnem razvoju s partnerjem Eli Lilly and Company (Lilly).
Industry: | Bio Therapeutic Drugs |
1180 Veterans Blvd
SOUTH SAN FRANCISCO
CALIFORNIA 94080
US
Izkaz poslovnega izida
- Annual
- Quarterly
Ljudje gledajo tudi
Še vedno iščete posrednika, ki mu lahko zaupate?
Pridružite se 530.000+ trgovcem po vsem svetu, ki so se odločili za trgovanje s Capital.com